PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report

Routine neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma prior to radical surgery is curative. With the increase in cancer immunotherapy, neoadjuvant immunotherapy has been used as an important complement to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Torip...

Full description

Saved in:
Bibliographic Details
Published inMedicine (Baltimore) Vol. 101; no. 2; p. e28591
Main Authors Yin, Huaqi, Yongkang, Ma, Bao, Guan, Shiming, Zhao, Chaohong, He, Tiejun, Yang
Format Journal Article
LanguageEnglish
Published United States Lippincott Williams & Wilkins 14.01.2022
Subjects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - surgery
Clinical Case Report
Cystectomy
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Gemcitabine
Humans
Immune Checkpoint Inhibitors - therapeutic use
Male
Middle Aged
Muscles - pathology
Neoadjuvant Therapy
Treatment Outcome
Urinary Bladder
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - surgery
Online AccessGet full text

Cover

More Information
Summary:Routine neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma prior to radical surgery is curative. With the increase in cancer immunotherapy, neoadjuvant immunotherapy has been used as an important complement to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Toripalimab is a recombinant, humanized IgG4 monoclonal antibody directed against programmed cell death protein 1 and received the first global approval for the treatment of unresectable or metastatic melanoma in China on December 17, 2018. A 57-year-old man was admitted to our hospital because of hematuria for 1 week. The patient was diagnosed pathologically with muscle-invasive bladder urothelial carcinoma. The patient received neoadjuvant toripalimab combined with gemcitabine therapy. The patient showed partial response. Subsequently, radical cystectomy was performed. Toripalimab combined with gemcitabine exhibited accurate antitumor activity and may be a promising novel neoadjuvant therapy for muscle-invasive urothelial carcinoma.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000028591